亚宝药业(600351.SH)：将太原制药62%的股权以8718.87万元转让给同享科技

Core Viewpoint - The company aims to optimize its asset structure and resource allocation, improve asset operation efficiency, and reduce management costs through the transfer of a significant stake in its subsidiary [1] Group 1: Transaction Details - The company signed a share transfer agreement with Tongxiang Technology on November 17, 2025, to transfer 62% of its controlling subsidiary Taiyuan Pharmaceutical for RMB 87.1887 million [1] - After the transaction, Tongxiang Technology will hold 95% of Taiyuan Pharmaceutical, while the company will retain a 5% stake [1] - Taiyuan Pharmaceutical will no longer be included in the company's consolidated financial statements following the completion of this transaction [1]